Fulcrum Therapeutics, Inc. (FULC) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to Fulcrum Territic's first quarter 2025 financial results and business update conference call. Currently all participants are on a listen-only mode. This call is being webcast live and can be accessed on the investor section of Fulcrum's website at www.fulcrumtx.com and is being recorded. Please be reminded that remarks during this call may contain forward-looking statements Meaning the meaning of the Private Securities Litigation and Form Act of 1995 may include statements about the company's future expectations and plans, clinical development timelines, and financial projections. While these forward-looking statements represent Farcom's view as of today, they should not be relied upon as representing the company's views in the future. Farcom may update these statements in the future, but is not taking on an obligation to do so. Please refer to Farcom's most recent filings the Securities and Exchange Commission for discussions of certain risks and uncertainties associated with the company's business. Leading the call today will be Alex Sapir, CEO and President of Fulcrum. Joining Alex on the call are Alan Musso, Chief Financial Officer. After providing updates on the company's key programs, there'll be a brief Q&A in which the Fulcrum management team will be available for questions. With that, it is my pleasure to turn the call over to Alex. Thank you, Livia, and good morning, everyone, and thanks for joining us today. So before jumping into the updates for the quarter, I just wanted to take a moment to welcome Dagon Ha, the newest member of the Fulcrum management team, as our senior vice president, head of strategy and business development. Now, Dagon is no stranger to Fulcrum, nor to the sickle cell space. For the past five years, Dagon w...